A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- Clinical diagnosis of relapsed/refractory B-cell Malignancies per International
Workshop Group (IWG) 2007 criteria or 2008 International Workshop on CLL (IWCLL)
criteria

- Follicular Lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients must have
at least 1 lesion that can be biopsied at screening and on treatment

- Men and women 18 and older

- Women of childbearing potential (WOCBP) and men must use highly effective methods of
contraception

- Eastern Cooperative Oncology Group (ECOG) of 0 to 1

- Progressed or refractory to at least 1 prior line of standard therapy; for dose
expansion cohort a maximum of 4 lines of cytotoxic chemotherapy-containing regimens

Exclusion Criteria:

- Active or progressing brain metastases

- Other concomitant malignancies (with some exceptions per protocol)

- Active or history of autoimmune disease

- Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune
deficiency syndrome (AIDS)

- History of any hepatitis (A,B or C)

- History of hepatitis

- Known current drug or alcohol abuse

- Active tuberculosis (TB)

- Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
including but not limited to, Anti-Programmed Death-1 (anti-PD-1), Anti-Programmed
Death-Ligand1 (anti-PD-L1), anti-CD137, Anti Cytotoxic T lymphocyte-associated
antigen 4 (anti-CTLA4), Anti-Glucocorticoid-induced tumor necrosis factor receptor
(anti-GITR)